Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

[1]  Y. Liu,et al.  Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer. , 2016, Future oncology.

[2]  Hui Wang,et al.  Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis. , 2015, Genetics and molecular research : GMR.

[3]  R. Salgia,et al.  PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma* , 2015, The Journal of Biological Chemistry.

[4]  R. Salgia,et al.  Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC). , 2015 .

[5]  Xin Zhou,et al.  Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[6]  H. Weng,et al.  CXCR4 over-expression and survival in cancer: A system review and meta-analysis , 2014, Oncotarget.

[7]  M. Uhlik,et al.  Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models , 2014, Molecular Cancer Therapeutics.

[8]  K. Griffith,et al.  Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.

[9]  A. Godwin,et al.  A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer , 2014, Front. Oncol..

[10]  H. Li,et al.  1464OCLINICAL VALUE OF CIRCULATING TUMOR CELLS IN MONITORING TREATMENT RESPONSE IN CHINESE PATIENTS WITH SMALL CELL LUNG CANCER. , 2014, Annals of Oncology.

[11]  R. Salgia,et al.  1472PPHASE II STUDY OF CARBOPLATIN/ETOPOSIDE PLUS LY2510924, A CXCR4 PEPTIDE ANTAGONIST, VERSUS CARBOPLATIN/ETOPOSIDE IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Rossi,et al.  Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. , 2014, Lung cancer.

[13]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[14]  M. Galsky,et al.  A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer , 2014, Clinical Cancer Research.

[15]  A. Masago,et al.  Circulating tumor cells as a prognostic factor in patients with small cell lung cancer , 2014, Oncology letters.

[16]  M. Socinski,et al.  Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. , 2012, Lung cancer.

[17]  H. Groen,et al.  Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Yukiko Nakamura,et al.  Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Motoyama,et al.  Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. , 2010, Lung cancer.

[21]  Beverly A. Teicher,et al.  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.

[22]  J. Maris,et al.  CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation , 2009, Molecular Cancer.

[23]  G. Botti,et al.  A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. , 2009, Lung cancer.

[24]  R. Elashoff,et al.  CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer , 2009, BMC Cancer.

[25]  Li Zhang,et al.  Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  J. Burger,et al.  CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells , 2005, Oncogene.

[27]  F. Balkwill.  The significance of cancer cell expression of the chemokine receptor CXCR4. , 2004, Seminars in cancer biology.

[28]  Tanja Hartmann,et al.  Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells , 2003, Oncogene.

[29]  Ravi Salgia,et al.  Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. , 2002, Cancer research.

[30]  H. Niell.  Extensive stage small cell lung cancer , 2001, Current treatment options in oncology.

[31]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[32]  Baocun Sun,et al.  Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. , 2014, International journal of clinical and experimental pathology.

[33]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[34]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[35]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.